by Green Griffith | Jan 3, 2019 | IP News
The Bill (H.R. 7251) would require companies desiring to launch a generic or biosimilar product to choose between an IPR and the Hatch-Waxman/BPCIA framework. Members of the US House and Senate, on December 11, 2018, jointly introduced the Hatch-Waxman Integrity Act...
by Green Griffith | Nov 30, 2018 | Firm News
Green Griffith Partner, Caryn Borg-Breen, will be a featured speaker at the Morning Lineup Live event at the University Club in Chicago on December 5, 2018. Green Griffith is pleased to announce that founding partner, Caryn Borg-Breen, will participate in a panel...
by Green Griffith | Nov 28, 2018 | Firm News
Chris Griffith and Jeff Ward were invited to attend the 3rd China Pharma IP Summit in Beijing held on October 24-26, 2018. This event focused on a variety of IP topics pertinent to pharma stakeholders located in Asia, including pharma-related IP policies in China, as...
by Green Griffith | Nov 11, 2018 | IP News
The United States Patent and Trademark Office (USPTO) has discarded the “broadest reasonable interpretation” claim construction standard for PTAB proceedings effective for petitions filed on or after November 13, 2018. The USPTO, in a final rule (a copy of...
by Green Griffith | Nov 7, 2018 | IP News
A Delaware District Court has determined that drug substance batches manufactured pursuant to a continued process verification program for a biosimilar product were not protected under the “safe harbor” defense. The Biologics Price Competition and Innovation Act of...
